Denosumab as an immune modulator in HER2-negative early breast cancer: results of the window-of-opportunity D-BIOMARK clinical trial

Abstract Background The RANK pathway has been extensively investigated for its role in bone resorption; however, its significance extends beyond bone metabolism. Preclinical models suggest that inhibition of RANK signaling can prevent mammary tumor development by reducing proliferation and tumor cel...

Full description

Bibliographic Details

Published in:	Breast Cancer Research
Main Authors:	Andrea Vethencourt, Eva M. Trinidad, Eduard Dorca, Anna Petit, M. Teresa Soler-Monsó, Marina Ciscar, Alexandra Barranco, Gema Pérez-Chacón, María Jimenez, Mario Rodríguez, Clara Gomez-Aleza, Elvira Purqueras, Enrique Hernández-Jiménez, Ander Urruticoechea, Idoia Morilla, Isaac Subirana, Amparo García-Tejedor, Miguel Gil-Gil, Sonia Pernas, Catalina Falo, Eva Gonzalez-Suarez
Format:	Article
Language:	English
Published:	BMC 2025-05-01
Subjects:	Breast cancer RANK RANKL Denosumab TILs Immune enhancer
Online Access:	https://doi.org/10.1186/s13058-025-01996-w